Rocket Pharmaceuticals, Inc. (RCKT)
Largest Insider Buys in Sector
RCKT Stock Price History Chart
RCKT Stock Performance
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell …
Insider Activity of Rocket Pharmaceuticals, Inc.
Over the last 12 months, insiders at Rocket Pharmaceuticals, Inc. have bought $0 and sold $12.4M worth of Rocket Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Rocket Pharmaceuticals, Inc. have bought $19.39M and sold $19.39M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,355,932 shares for transaction amount of $20M was made by WONG RODERICK (director) on 2022‑10‑06.
List of Insider Buy and Sell Transactions, Rocket Pharmaceuticals, Inc.
| 2024-10-31 | Sale | See Remarks | 3,080 0.0034% | $16.63 | $51,205 | +1.14% | ||
| 2024-10-31 | Sale | See Remarks | 917 0.001% | $16.63 | $15,245 | +1.14% | ||
| 2024-08-16 | Sale | CEO | 9,650 0.0105% | $18.50 | $178,564 | 0.00% | ||
| 2024-08-16 | Sale | See Remarks | 3,989 0.0043% | $18.50 | $73,812 | 0.00% | ||
| 2024-08-16 | Sale | General Counsel | 1,027 0.0011% | $18.50 | $19,004 | 0.00% | ||
| 2024-08-16 | Sale | See Remarks | 1,064 0.0012% | $18.50 | $19,688 | 0.00% | ||
| 2024-07-22 | Sale | See Remarks | 812 0.0009% | $23.02 | $18,688 | -23.13% | ||
| 2024-07-08 | Sale | See Remarks | 3,026 0.0032% | $20.39 | $61,715 | 0.00% | ||
| 2024-05-16 | Sale | CEO | 9,790 0.0108% | $23.35 | $228,597 | -16.46% | ||
| 2024-05-16 | Sale | See Remarks | 4,046 0.0045% | $23.35 | $94,474 | -16.46% | ||
| 2024-05-16 | Sale | General Counsel | 1,048 0.0012% | $23.35 | $24,471 | -16.46% | ||
| 2024-05-16 | Sale | See Remarks | 1,079 0.0012% | $23.35 | $25,195 | -16.46% | ||
| 2024-04-22 | Sale | See Remarks | 833 0.0009% | $22.87 | $19,051 | -13.36% | ||
| 2024-04-15 | Sale | director | 10,000 0.0111% | $24.05 | $240,520 | -13.18% | ||
| 2024-04-12 | Sale | director | 70,000 0.0779% | $24.36 | $1.71M | -13.81% | ||
| 2024-04-08 | Sale | See Remarks | 12,532 0.014% | $24.64 | $308,763 | -14.15% | ||
| 2024-03-21 | Sale | director | 274,000 0.3107% | $28.43 | $7.79M | -22.65% | ||
| 2024-03-21 | Sale | See Remarks | 2,490 0.0028% | $28.10 | $69,979 | -22.65% | ||
| 2024-02-29 | Sale | See Remarks | 10,000 0.0113% | $29.84 | $298,450 | -24.98% | ||
| 2024-02-29 | Sale | General Counsel | 4,100 0.0046% | $29.33 | $120,257 | -24.98% |
Insider Historical Profitability
| Shah Gaurav | CEO | 718419 0.7881% | $13.07 | 1 | 9 | <0.0001% |
| Patel Kinnari | See Remarks | 396983 0.4355% | $13.07 | 2 | 6 | +84.02% |
| SOUTHWELL DAVID P | director | 114784 0.1259% | $13.07 | 1 | 5 | +4.41% |
| WONG RODERICK | director | 17628567 19.3387% | $13.07 | 1 | 0 | +5.69% |
| RTW INVESTMENTS, LP | 15460119 16.9599% | $13.07 | 3 | 1 | <0.0001% |
Institutional Investor Ownership
| RTW Investments, LP | $476.51M | 19.48 | 17.69M | 0% | +$0 | 7.14 | |
| Wellington Management Company | $246.67M | 10.09 | 9.16M | +11.69% | +$25.82M | 0.04 | |
| BlackRock | $159.75M | 6.53 | 5.93M | <0.01% | -$7,219.92 | <0.01 | |
| The Vanguard Group | $144.69M | 5.92 | 5.37M | -1.41% | -$2.07M | <0.01 | |
| State Street | $112.96M | 4.62 | 4.19M | +29.76% | +$25.91M | 0.01 |